[Suppression of non-specific bronchial hyperreactivity by DSCG (Disodium cromoglycate) and ipratropium bromide (author's transl)].
The protective activity of DSCG was investigated in 18 children with established non-specific bronchial hyperreactivity induced by bronchial challenge with acetylcholine. Ipratropium bromide, the anticholinergic agent, was used for comparison. DSCG showed a statistically significant inhibitory action on the decrease in specific airway conductance. Besides the well-established inhibition of mast cell degranulation a direct action on cholinergic irritative receptors seems likely. Application of DSCG in immunologically ill-defined forms of bronchial asthma may be considered. As expected, the direct acetylcholine antagonist, ipratropium bromide, showed an overall protective effect.
D000293:Adolescent; D000403:Airway Resistance / Q000187:drug effects; D001249:Asthma / Q000188:drug therapy*; D001286:Atropine Derivatives / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004205:Cromolyn Sodium / Q000627:therapeutic use*; D006801:Humans; D009241:Ipratropium / Q000627:therapeutic use*; D012130:Respiratory Hypersensitivity / Q000188:drug therapy*
D001286:Atropine Derivatives; D009241:Ipratropium; D004205:Cromolyn Sodium
Zur Beeinflussung der unspezifischen bronchialen Hyperreaktivität durch Dinatriumcromoglycat (DNCG) und Ipratropiumbromid.